Clinical Associate Professor, Department of Medicine, Faculty of Medicine, UBC
Department of Medical Oncology, BC Cancer Agency
BC Cancer Agency
2410 Lee Avenue
Victoria, BC

Professional Roles

  • September 1996 – present – Medical Oncologist, British Columbia Cancer Agency – Vancouver Island Centre (BC Cancer Agency-VIC)
  • December 2004-September 2006; January 2008-January 2009 – Medical Oncology Professional Practice Leader BC Cancer Agency-VIC (Interim)
  • April 2006 – December 2009 – Physician Leader, Clinical Trials Unit, BC Cancer Agency-VIC
  • July 1996 – present – Breast Tumour Group member, BC Cancer Agency
  • July 1996 – present – Lymphoma Tumour Group member, BC Cancer Agency
  • 1999 – present – Chair of Lymphoma site team, BC Cancer Agency-VIC
  • 1999 – present – Chair of Morbidity and Mortality rounds, BC Cancer Agency-VIC
  • 2014 – present – Medical Advisory Committee, BC Cancer Agency, Vancouver Island Centre representative
  • 2010 – present – Clinical Principal Investigator, PREDICT (Personal Response Determinants in Cancer Therapy) project, BC Cancer Agency
  • 2009 – present – Principal Investigator, Biology of Lymphoid Cancer, BC Cancer Agency-VIC (Dr. J Connors is PI for the provincial project)
  • 2007 – present – Clinical Principal Investigator, Immune Response in Lymphoma Project, BC Cancer Agency


Doctor of Philosophy, Pathobiology and Laboratory Medicine, University of Toronto
Medical Doctor, Queens University
Bachelor of Science (Hons), Biochemistry and Chemistry, McMaster University
Recent Publications:
  • A novel histone H4 variant regulates rDNA transcription in breast cancer Long, MengPing; Sun, Xulun; Shi, Wenjin; Yanru, An; Leung, Tsz Chui Sophia; Cheema, Manjinder; Ding, Dongbo; MacPherson, Nicol; Nelson, Christopher J; Ausio, Juan; Yan, Yan; Ishibashi, Toyotaka. Nucleic Acid research
  • Nielsen JS, Chang AR, Wick DA, Sedgwick CG, Zong Z, Mungall AJ, Martin SD, Kinloch NN, Ott-Langer, S, Brumme ZL, Treon SP, Connors JM, Gascoyne RD, Webb JR, Berry BR, Morin RD, Macpherson N, and Nelson BH. Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. OncoImmunology 6(7):e1321184 (2017). Journal impact factor: 6.27.
  • Nielsen JS, Sedgwick CG, Shahid A, Zong Z, Brumme ZL, Yu S, Liu LY, Kroeger DR, Treon SP, Connors JM, Gascoyne RD, Berry BR, Marra MA, Morin RD, Macpherson N, and Nelson BH. Toward personalized lymphoma immunotherapy: Identification of common driver mutations recognized by patient CD8+ T cells. Clinical Cancer Research 22(9): 2226-36 (2016). Journal impact factor: 8.74.
  • NR West, K Milne, P Truong, N Macpherson, B Nelson, P Watson Tumor infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Research, 13:R126 (08 Dec 2011)
  • Macpherson N, Belch A, Taylor M, Sutherland J, Czaykowski P, Connors J. Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin’s lymphoma: a phase II study. Leukemia & Lymphoma, 47 (7) :1327-32, 2006 July
  • Prentice LM, Shadeo A, Lestou VS, Miller MA, deLeeuw RJ, Makretsov N, Turbin D, Brown LA, Macpherson N, Yorida E, Cheang MC, Bentley J, Chia S, Nielsen TO, Gilks CB, Lam W, Huntsman DG, NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 24 (49) : 7281-9, 2005 Nov 10.
  • Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, Macpherson N, O’Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. Journal of Clinical Oncology. 23 (22) :5027-33, 2005 Aug 1.
  • Long BJ, Jelovac D, Handratta V, Thiantanawat A, Macpherson NA, Ragaz J, Goloubeva OG, Brodie AM. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Journal of the National Cancer Institute. 96 (6):456-65, 2004 Mar.17.
  • Lesperance ML, Olivotto IA, Forde N, Zhao Y, Speers C, Foster H, Tsae M, Macpherson N, Hoffer A: Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 76:137-43., 2002
  • Hembury TA, Lee B, Gascoyne RD, Macpherson N, Yang B, House N, Medeiros LJ, His ED: Primary cutaneous diffuse large B-cell lymphoma: a clinicopathologic study of 15 cases. Am J Clin Pathol 117:574-80., 2002
  • Macpherson N, Klasa RJ, Gascoyne R, et al: Treatment of elderly Hodgkin’s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma 43:1395-402., 2002
  • Mirza I, Macpherson N, Paproski S, et al: Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 20:647-55., 2002
  • Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, Becker L, Carneiro F, Macpherson N, Horsman D, Poremba C, Sorensen PH : Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2:367-76., 2002
  • Brodie AM, Lu Q, Long BG, Fulton A, Chen T, Macpherson NA, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH. Aromatase and COX-2 expression in human breast cancers. Journal of Steroid Biochemistry and Molecular Biology. 79(1-5):41-7, 2001 Dec.
  • Macpherson NA, Lesack D, Klasa R, Horsman D, Connors J, Barnett M, Gascoyne RD. Small non-cleaved non-Burkitt’s (Burkitt-like) lymphoma: cytogenetics predict for outcome and reflect clinical presentation. J Clin Onc; 17(5); 1558-1567, 1999.
  • Skinnider BF, Clement PB, Macpherson NA, Gascoyne RD, Viswanatha DS. Primary non-Hodgkins Lymphoma and malakoplakia of the vagina: a case report. Human Pathol 30(7); 871-874, 1999.
  • O’Reilly SE, Connors JM, Macpherson NA, Klasa R, Hoskins P. Malignant Lymphomas in the Elderly. Clinics in Geriatric Medicine (1997) May (13) No 2, 215. Macpherson NA. A primer on the immuno-conjugate therapy of non-Hodgkin’s lymphoma. Current Oncology (1997) Dec, Vol 4, No 4. 223-8
  • Macpherson NA, Moscarello MA, Goldberg DM. Aminoaciduria is an earlier marker of renal tubular damage than conventional renal disease markers in the gentamicin-rat model of acute renal failure. Clin Invest Med (1991) Apr 14(2) 101-110.
  • Macpherson NA, Moscarello MA, Goldberg DM, Ish-Shalom N, Arbus GS. Aminoaciduria as a marker of acute renal transplant rejection – a patient study. Clin Invest Med (1991) Apr 14 (2) 111-9.
Awards & Recognition:
  1. CAMO (Canadian Association of Medical Oncologists)/Glaxo-Wellcome Fellowship 1996-1997. Award declined in order to take up position as Medical Oncologist at the B.C. Cancer Agency.
  2. Shane Fellowship from Order of the Eastern Star 1996-1997. Award declined in order to take up position as Medical Oncologist at B.C. Cancer Agency.
  3. Travel Scholarship from International Society of Nephrology to present my research at Xth International Congress of Nephrology (London, 1987) and Mechanisms of Nephritis Symposium (Cambridge 1987).
  4. Clin. Med. Award presented by the Canadian Society of Clinical Chemists for research presented at Annual meeting of Canadian Society of Clinical Chemists (Ottawa, 1987).
  5. Student Award from Canadian Society for Clinical Investigation, received at Canadian Society for Clinical Investigation Annual meeting (Toronto, 1986)
  • BioCanRx: Biotherapeutics for Cancer Treatment, 2016-2018 ($358,186) Adoptive T cell therapy targeting patient-specific driver mutations in lymphoma Clinical co-PI (PI: Dr. Brad Nelson)
  • Canadian Cancer Society Research Initiative; Innovation to Impact. 2016-2019 ($450,000) Adoptive T-cell therapy targeting patient-specific driver mutations in lymphoma Co-applicant – Clinical principal investigator (PI: Dr. Brad Nelson)
  • International Waldenstrom’s Macroglobulinemia Foundation & Waldenstrom’s Macroglobulinema Foundation of Canada, 2014-2016 ($370,748) Mutant MYD88: A target for adoptive T-cell therapy of WM Co-investigator (PI: Dr. Brad Nelson and Dr. Julie Nielsen)
  • Canadian Cancer Society Research Initiative. 2013-2015 ($200,000) The mutated lymphoma genome: A target for therapeutic vaccination Co-investigator (PI: Dr. Brad Nelson)
  • The Waldenstrom’s Macroglobulinemia Foundation of Canada & International Waldenstrom’s Macroglobulinemia Foundation, 2010-2012 ($99,935) The immune response to Waldenstrom’s Macroglobulinemia: Implications for Immunotherapy. Co-Applicant (PI: Dr. Brad Nelson)
  • BC Cancer Foundation, 2007-2010 ($353,330) Immune Response to Lymphoma. Co-Principal Investigator (Co-PI Dr. Brad Nelson)
  • Terry Fox Research Initiative (TFRI), 2009-2010 ($120,000) The Pan-Canadian Breast Biomarker Network Pilot. Co-investigator (PI: Dr. Peter Watson)
  • Michael Smith Foundation for Health Research, 2005-2007 ($100,000) Telehealth grant. Co-investigator (PI: Dr. Brian Weinerman)
  • Clinical teaching for medical students at the BC Cancer Agency (2005-present); 683 hours.
  • Ward-bedside clinical skills teaching for 2nd year Medical Students at the University Hospital, of British Columbia (1999-2003)
  • University of Victoria, Clinical Cancer Care, Biology course #470, annual lecture on Systemic Therapy (2003-present)
  • External reviewer of MSc thesis submitted by Sara Hahn, University of Victoria. “The identification of tumour-associated antigens on the cell membrane of myeloma cells as targets for multiple myeloma therapy”.
  • External reviewer of MSc thesis submitted by Tanis Gail Whitmore, Department of Biology, University of Victoria. “Identification of Differentially Expressed Genes during the Progression of Prostate Cancer from Androgen Dependence to Independence in the LNCaP in vivo Tumour Model”.